Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pregnancy associated plasma protein a

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Pregnancy associated plasma protein a. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2016-004282-31 Sponsor Protocol Number: V14-11056 Start Date*: 2017-03-15
    Sponsor Name:Vivolux AB
    Full Title: VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005847-29 Sponsor Protocol Number: MM-VPD-2011 Start Date*: 2012-02-15
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose Therapy
    Medical condition: Multiple Myeloma patients candidate to high-dose therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003753-33 Sponsor Protocol Number: 095 Start Date*: 2009-01-14
    Sponsor Name:Merck & Co., Inc.
    Full Title: Estudio abierto internacional multicéntrico de vorinostat (MK-0683) en combinación con bortezomib en pacientes con mieloma múltiple recidivante y resistente al tratamiento An International, Multic...
    Medical condition: Mieloma múltiple multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004349-35 Sponsor Protocol Number: 7001 Start Date*: 2021-02-02
    Sponsor Name:Klinisk Forskningsenhed, Medicinsk Afdeling, Hæmatologisk Afsnit, Sygehus Lillebælt, Vejle Sygehus
    Full Title: Melphalan flufenamide (melflufen) and Dexamethasone re-induction in Daratumumab-refractory Multiple Myeloma as an Adjunct to Continued Daratumumab (MERMAID)
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004138-17 Sponsor Protocol Number: CA200004 Start Date*: 2008-05-13
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse
    Medical condition: Patients with multiple myeloma in first relapse after failure of previous anti-cancer therapy and/or bone marrow transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) ES (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003893-42 Sponsor Protocol Number: AUTO2-MM1 Start Date*: 2017-03-28
    Sponsor Name:Autolus Limited
    Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractor...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001069-35 Sponsor Protocol Number: IIBSP-EDA-2020-18 Start Date*: 2021-07-06
    Sponsor Name:Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau – IIB Sant Pau
    Full Title: Impact of Exercise and Mediterranean diet vs Aspirin on live-birth rate and cardiovascular programming in In Vitro Fertilization (MEDITATE-IVF): a Randomized Study.
    Medical condition: Cumulative live-birth rate.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004837-34 Sponsor Protocol Number: CAEB1102-300A Start Date*: 2019-06-18
    Sponsor Name:Aeglea Biotherapeutics, Inc.
    Full Title: PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and ...
    Medical condition: Arginase 1 Deficiency Hyperargininemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062695 Arginase deficiency PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004151-16 Sponsor Protocol Number: 209628 Start Date*: 2021-11-22
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participa...
    Medical condition: Multiple myeloma = cancer of blood cells in the bone marrow
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004185-34 Sponsor Protocol Number: 54767414MMY2065 Start Date*: 2019-05-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Mu...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) FR (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004152-10 Sponsor Protocol Number: EMPATHY Start Date*: 2020-01-30
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a sequential OFF-ON-OFF S...
    Medical condition: Obesity Renal chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    21.1 100000004857 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004785-10 Sponsor Protocol Number: LSH-17-001 Start Date*: 2018-12-04
    Sponsor Name:Landspitali University Hospital
    Full Title: Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM)
    Medical condition: Patients diagnosed with smoldering multiple myeloma (SMM) or active multiple myeloma (MM) will be invited to participate in the study.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    20.0 100000004864 10075894 Smoldering myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022293-14 Sponsor Protocol Number: ANRS146OPTIMAL Start Date*: 2012-08-22
    Sponsor Name:Inserm-ANRS
    Full Title: Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi...
    Medical condition: HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000860-14 Sponsor Protocol Number: GR-OG-279239-03 Start Date*: 2018-02-27
    Sponsor Name:Genera Research Ltd
    Full Title: Patient and evaluator blinded non-inferiority study on safety, tolerability and lumbar fusion efficacy of a single administration of Osteogrow (rhBMP6 in autologous blood coagulum (ABC) carrier) in...
    Medical condition: Lumbar spine single segment destabilization caused by degenerative disc disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10050505 Spinal fusion surgery PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000595-42 Sponsor Protocol Number: ESR-18-13834 Start Date*: 2019-07-08
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: A randomized, double-blind, placebo controlled, parallel, multicentre study of the effects of 12-weeks of sodium zirconium cyclosilicate (Lokelma) on albuminuria (UACR) in patients with diabetes an...
    Medical condition: Treatment for proteinuria in type 1 or type 2 diabetes with hyperkalemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003384-25 Sponsor Protocol Number: DTX301-CL301 Start Date*: 2022-12-16
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients with Late-Onset...
    Medical condition: Late-onset Ornithine transcarbamylase (OTC) deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10071107 Ornithine transcarbamylase deficiency LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006297-23 Sponsor Protocol Number: 06/Q0701/34 Start Date*: 2007-06-12
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust
    Full Title: A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy
    Medical condition: HIV during pregnancy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020180 HIV positive LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002012-27 Sponsor Protocol Number: 0708 Start Date*: 2019-12-09
    Sponsor Name:University of Leicester
    Full Title: A Single Centre, Open-label, Single-group Exploratory Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients with Immunoglobulin A Nephropathy
    Medical condition: Immunoglobulin A (IgA) nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000287-42 Sponsor Protocol Number: I15015 Start Date*: 2016-05-18
    Sponsor Name:CHU de Limoges
    Full Title: A Multicentre Open label Phase II study of Daratumumab in AL Amyloidosis Patients not in VGPR or Better
    Medical condition: AL Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10035227 Plasma cell neoplasms HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022395-31 Sponsor Protocol Number: AC-004-EU Start Date*: 2010-10-07
    Sponsor Name:E.M.N. - EUROPEAN MYELOMA NETWORK
    Full Title: A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL...
    Medical condition: AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035227 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Ongoing) DK (Completed) GB (GB - no longer in EU/EEA) GR (Ongoing) ES (Ongoing) DE (Completed) CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:17:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA